Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 26
1998 105
1999 99
2000 87
2001 96
2002 112
2003 107
2004 104
2005 111
2006 96
2007 101
2008 98
2009 100
2010 116
2011 105
2012 101
2013 87
2014 103
2015 105
2016 110
2017 101
2018 97
2019 107
2020 114
2021 104
2022 110
2023 102
2024 99
2025 103
2026 65

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,696 results

Results by year

Filters applied: . Clear all
Page 1
As-Needed Albuterol-Budesonide in Mild Asthma.
LaForce C, Albers F, Danilewicz A, Jeynes-Ellis A, Kraft M, Panettieri RA Jr, Rees R, Bardsley S, Dunsire L, Harrison T, Sobande O, Surujbally R, Trudo F, Cappelletti C, Papi A, Beasley R, Chipps BE, Israel E, Pandya H, Clancy M, Bacharier LB; BATURA Investigators. LaForce C, et al. N Engl J Med. 2025 Jul 10;393(2):113-124. doi: 10.1056/NEJMoa2504544. Epub 2025 May 19. N Engl J Med. 2025. PMID: 40388330 Clinical Trial.
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
Allergic Rhinitis: A Review.
Bernstein JA, Bernstein JS, Makol R, Ward S. Bernstein JA, et al. JAMA. 2024 Mar 12;331(10):866-877. doi: 10.1001/jama.2024.0530. JAMA. 2024. PMID: 38470381 Review.
Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.
Manley BJ, Kamlin COF, Donath SM, Francis KL, Cheong JLY, Dargaville PA, Dawson JA, Jacobs SE, Birch P, Resnick SM, Schmölzer GM, Law B, Bhatia R, Bach KP, de Waal K, Travadi JN, Koorts PJ, Berry MJ, Lui K, Rajadurai VS, Chandran S, Kluckow M, Cloete E, Broom MM, Stark MJ, Gordon A, Kodur V, Doyle LW, Davis PG, McKinlay CJD; PLUSS Trial Investigators. Manley BJ, et al. JAMA. 2024 Dec 10;332(22):1889-1899. doi: 10.1001/jama.2024.17380. JAMA. 2024. PMID: 39527075 Free PMC article. Clinical Trial.
Budesonide-formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hatter L, Holliday M, Oldfield K, Kearns C, Barry T, Black M, Bruce P, Colman A, Dickinson E, Eathorne A, Harwood M, Hills T, Lamb R, Kerse K, Krishnamoorthy S, Martindale J, Semprini A, Shortt N, McNamara D, Byrnes CA, Dalziel SR, Bush A, Weatherall M, Beasley R; CARE study team. Hatter L, et al. Lancet. 2025 Oct 4;406(10511):1473-1483. doi: 10.1016/S0140-6736(25)00861-X. Epub 2025 Sep 28. Lancet. 2025. PMID: 41033330 Clinical Trial.
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials.
Papi A, Wise RA, Jackson DJ, Lugogo N, Chen R, Trasieva T, Obasi C, Movitz C, Helman J, Salter P, Springer K, Bondoc M, Shah M, Knappenberger K, Bowen K, Pandya H, Megally A, Patel M; KALOS and LOGOS study investigators. Papi A, et al. Lancet Respir Med. 2026 Apr;14(4):350-362. doi: 10.1016/S2213-2600(25)00457-6. Epub 2026 Feb 12. Lancet Respir Med. 2026. PMID: 41692019 Clinical Trial.
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Papi A, Chipps BE, Beasley R, Panettieri RA Jr, Israel E, Cooper M, Dunsire L, Jeynes-Ellis A, Johnsson E, Rees R, Cappelletti C, Albers FC. Papi A, et al. N Engl J Med. 2022 Jun 2;386(22):2071-2083. doi: 10.1056/NEJMoa2203163. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569035 Clinical Trial.
Eosinophilic Esophagitis: A Review.
Muir A, Falk GW. Muir A, et al. JAMA. 2021 Oct 5;326(13):1310-1318. doi: 10.1001/jama.2021.14920. JAMA. 2021. PMID: 34609446 Free PMC article. Review.
Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.
Ambalavanan N, Carlo WA, Nowak KJ, Wiener LE, Cosby SS, Bhatt AJ, Watterberg KL, Poindexter BB, Keszler M, D'Angio CT, Brion LP, Narendran V, Rau CA, Cotten CM, Laughon MM, Das A, Rysavy MA, Hibbs AM, Fuller J, Puopolo KM, Katheria A, Patel RM, Bermick JR, Laptook AR, Prelipcean I, Wyckoff MH, Moore R, Merhar SL, Ohls RK, Yoder BA, Perez M, Ghavam S, Meyer LR, Chock VY, DeMauro SB, Jackson WM, Handa D, Walsh MC; National Institute of Child Health and Human Development Neonatal Research Network. Ambalavanan N, et al. JAMA. 2025 Oct 28;334(16):1452-1462. doi: 10.1001/jama.2025.16450. JAMA. 2025. PMID: 41026481 Free PMC article. Clinical Trial.
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, Rossman K, St Rose E, Trivedi R, Ballal S, Darken P, Aurivillius M, Reisner C, Dorinsky P. Martinez FJ, et al. Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-564. doi: 10.1164/rccm.202006-2618OC. Am J Respir Crit Care Med. 2021. PMID: 33252985 Free PMC article. Clinical Trial.
2,696 results